Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection
- PMID: 20096804
- PMCID: PMC2910421
- DOI: 10.1016/j.drudis.2010.01.004
Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection
Abstract
The HIV replication cycle offers multiple targets for chemotherapeutic intervention, including the viral exterior envelope glycoprotein, gp120; viral co-receptors CXCR4 and CCR5; transmembrane glycoprotein, gp41; integrase; reverse transcriptase; protease and so on. Most currently used anti-HIV drugs are reverse transcriptase inhibitors or protease inhibitors. The expanding application of simulation to drug design combined with experimental techniques have developed a large amount of novel inhibitors that interact specifically with targets besides transcriptase and protease. This review presents details of the anti-HIV inhibitors discovered with computer-aided approaches and provides an overview of the recent five-year achievements in the treatment of HIV infection and the application of computational methods to current drug design.
2010 Elsevier Ltd. All rights reserved.
Figures


Similar articles
-
New developments in anti-HIV chemotherapy.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):258-75. doi: 10.1016/s0925-4439(02)00089-3. Biochim Biophys Acta. 2002. PMID: 12084468 Review.
-
Novel compounds in preclinical/early clinical development for the treatment of HIV infections.Rev Med Virol. 2000 Jul-Aug;10(4):255-77. doi: 10.1002/1099-1654(200007/08)10:4<255::aid-rmv282>3.0.co;2-6. Rev Med Virol. 2000. PMID: 10891872 Review.
-
New anti-HIV agents and targets.Med Res Rev. 2002 Nov;22(6):531-65. doi: 10.1002/med.10021. Med Res Rev. 2002. PMID: 12369088 Review.
-
New developments in anti-HIV chemotherapy.Curr Med Chem. 2001 Nov;8(13):1543-72. doi: 10.2174/0929867013371842. Curr Med Chem. 2001. PMID: 11562282 Review.
-
Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.Expert Opin Drug Discov. 2015 Dec;10(12):1271-81. doi: 10.1517/17460441.2015.1083007. Epub 2015 Sep 15. Expert Opin Drug Discov. 2015. PMID: 26372893 Review.
Cited by
-
Applications of artificial intelligence to drug design and discovery in the big data era: a comprehensive review.Mol Divers. 2021 Aug;25(3):1643-1664. doi: 10.1007/s11030-021-10237-z. Epub 2021 Jun 10. Mol Divers. 2021. PMID: 34110579 Review.
-
Identification of HIV inhibitors guided by free energy perturbation calculations.Curr Pharm Des. 2012;18(9):1199-216. doi: 10.2174/138161212799436421. Curr Pharm Des. 2012. PMID: 22316150 Free PMC article. Review.
-
Advantages of Structure-Based Drug Design Approaches in Neurological Disorders.Curr Neuropharmacol. 2017 Nov 14;15(8):1136-1155. doi: 10.2174/1570159X15666170102145257. Curr Neuropharmacol. 2017. PMID: 28042767 Free PMC article. Review.
-
The (5Z)-5-Pentacosenoic and 5-Pentacosynoic Acids Inhibit the HIV-1 Reverse Transcriptase.Lipids. 2015 Oct;50(10):1043-50. doi: 10.1007/s11745-015-4064-2. Epub 2015 Sep 7. Lipids. 2015. PMID: 26345647 Free PMC article.
-
Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.PLoS One. 2014 Nov 13;9(11):e111923. doi: 10.1371/journal.pone.0111923. eCollection 2014. PLoS One. 2014. PMID: 25393106 Free PMC article.
References
-
- Girard MP, et al. A review of vaccine research and development: the human immunodeficiency virus (HIV) Vaccine. 2006;24:4062–4081. - PubMed
-
- Barbaro G, et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des. 2005;11:1805–1843. - PubMed
-
- Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res. 2002;55:15–25. - PubMed
-
- Greene WC. The brightening future of HIV therapeutics. Nat Immunol. 2004;5:867–871. - PubMed
-
- Hazuda D, et al. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol. 2009;49:377–394. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical